The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor
Livia Stanger(University of Michigan), Michael Holinstat(University of Michigan), Andrew D. White(University of Michigan), Björn Dahlöf(Thermo Fisher Scientific (Sweden)), Devin Gilmore(University of Michigan), Catherine Luke(University of Michigan), Andrew Rickenberg(University of Michigan), Pooja Yalavarthi(University of Michigan), Niklas Bergh(Sahlgrenska University Hospital), T. Andrea(University of Michigan), Adriana Yamaguchi(University of Michigan), Kiran Kumar(University of Michigan), Sylviane Lambert(University of Michigan)
Cited by 18
Related Papers
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
|The Lancet|1998|5.8k
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|1.6k
Nitric oxide‐induced mitochondrial fission is regulated by dynamin‐related GTPases in neurons
|The EMBO Journal|2006|649